Literature DB >> 27434289

Functional SNP in stem of mir-146a affects Her2 status and breast cancer survival.

Mahboobeh Meshkat1, Hamzeh Mesrian Tanha2, Marjan Mojtabavi Naeini3, Kamran Ghaedi2, Mohammad H Sanati4, Marzieh Meshkat1, Fatemeh Bagheri5.   

Abstract

In-silico investigation suggested a common variant within stem of miR-146a-5p precursor (rs2910164, n.60C>G) associated with breast cancer (BC) phenotypes. Our aim was computationally predicting possible targets of miR-146a-5p and probable rs2910164 mechanism of action in expression of phenotypes in BC. Additionally, a case-control study was designated to examine experimentally the correlation of mir-146a rs2910164 variant and BC phenotypes. In this study, 152 BC subjects and healthy controls were genotyped using RFLP-PCR. Allelic and genotypic association and Armitage's trend tests were run to investigate the correlation between the alleles and genotypes and expressed phenotypes of BC. Bioinformatics analyses introduce regulatory function of miR-146a-5p in numerous signaling pathways and impact of allele substitution upon mir-146a stem-loop stability. Logistic regression data represented the C allele of rs2910164 (OR = 4.00, p= 0.0037) as the risk allele and associated with Her2-positive phenotype. In a similar vein, data revealed the correlation of the C allele and cancer death less than two years in BC patients (OR = 2.65, p= 0.0217). Ultimately, unconditional logistical regression models suggested log-additive model for inheritance manner of rs2910164 in either Her2 status or BC survival (OR = 5.64, p= 0.0025 and OR = 3.13, p= 0.019, respectively). Using bioinformatics connected association of Her2 status to altered function of miR-146a-5p in regulation of focal adhesion and Ras pathway. Furthermore, computations inferred the association between death phenotype and studied SNP upon specific target genes of miR-146a-5p involved in focal adhesion, EGF receptor, Ras, ErbB, interleukin, Toll-like receptor, NGF, angiogenesis, and p53 feedback loops 2 signaling pathways. These verdicts may enhance our perceptions of how mir-146a rs2910164 affect expressed phenotypes in BC, and might have potential implications to develop BC treatment in future.

Entities:  

Keywords:  Breast cancer; Her2; cancer death; functional SNP; mir-146a

Mesh:

Substances:

Year:  2016        PMID: 27434289     DOI: 10.3233/CBM-160633

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  6 in total

1.  ErbB4 3'-UTR Variant (c.*3622A>G) is Associated with ER/PR Negativity and Advanced Breast Cancer.

Authors:  Maryam Tabatabian; Hamzeh Mesrian Tanha; Hossein Tabatabaeian; Samira Sadeghi; Kamran Ghaedi; Parisa Mohamadynejad
Journal:  Indian J Clin Biochem       Date:  2018-09-28

2.  MicroRNA-146 protects A549 and H1975 cells from LPS-induced apoptosis and inflammation injury.

Authors:  Qiang Wang; Dagang Li; Yuquan Han; Xiaoqian Ding; Tao Xu; Bingjian Tang
Journal:  J Biosci       Date:  2017-12       Impact factor: 1.826

3.  Expression of miR-146a-5p in breast cancer and its role in proliferation of breast cancer cells.

Authors:  Wei Gao; Jing Hua; Zhaoyang Jia; Jiping Ding; Zengwei Han; Yun Dong; Qing Lin; Yuan Yao
Journal:  Oncol Lett       Date:  2018-04-26       Impact factor: 2.967

4.  Investigating the association of rs2910164 with cancer predisposition in an Irish cohort.

Authors:  T P McVeigh; R J Mulligan; U M McVeigh; P W Owens; N Miller; M Bell; F Sebag; C Guerin; D S Quill; J B Weidhaas; M J Kerin; A J Lowery
Journal:  Endocr Connect       Date:  2017-09-12       Impact factor: 3.335

Review 5.  microRNAs Make the Call in Cancer Personalized Medicine.

Authors:  Simone Detassis; Margherita Grasso; Valerio Del Vescovo; Michela A Denti
Journal:  Front Cell Dev Biol       Date:  2017-09-22

6.  Meta-analysis of the association between three microRNA polymorphisms and breast cancer susceptibility.

Authors:  Kun Mu; Zi-Zheng Wu; Jin-Pu Yu; Wei Guo; Nan Wu; Li-Juan Wei; Huan Zhang; Jing Zhao; Jun-Tian Liu
Journal:  Oncotarget       Date:  2017-06-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.